### Diagnostic Approach to Polyuria and Polydipsia

David Bruyette, DVM, DACVIM Anivive Lifesciences 3750 Schaufele Rd, Suite 100 Long Beach, CA 90808 E-mail: David@anivive.com



www.veterinarydiagnosticinvestigation.com


### NORMAL WATER HOMEOSTASIS

Fluid Intake and Urine Output

Intact Pituitary – Renal Axis

Antidiuretic Hormone (ADH)

Intact Renal Medullary Interstitium




### NORMAL WATER HOMEOSTASIS


Fluid Intake and Urine Output


**Thirst** 


Plasma Osmolality
Serum Na concentration

Hypovolemia












(b) Recycling of salts and urea in vasa recta









#### **Key Proteins Involved in Regulation of Water Balance.**

Table 1. Key Proteins Involved in Regulation of Water Balance.				
Protein	Gene	Structure or Cell Type Relevant to Water Balance	Manifestation of Loss of Function*	Drugs That Target Protein
Arginine vasopressin	AVP	Neurons of supraoptic nucleus and paraventricular nucleus	Central diabetes insipidus	None
Vasopressin receptor				
V <sub>2</sub>	AVPR2	Renal thick ascending limb of the loop of Henle, distal convoluted tubule, connecting tubule, collecting duct	X-linked nephrogenic diabetes insipidus	Desmopressin acetate (agonist), tolvap- tan (antagonist)
$V_{1a}$	AVPR1A	Renal medullary vasculature (vasa recta)	None	Conivaptan (nonselec- tive V <sub>1a</sub> and V <sub>2</sub> antagonist)
Bumetanide-sensitive sodi- um–potassium–chlo- ride cotransporter	SLC12A1	Renal thick ascending limb of the loop of Henle	Type I Bartter's syndrome	Loop diuretics
Thiazide-sensitive sodium- chloride cotransporter	SLC12A3	Renal distal convoluted tubule	Gitelman's syndrome	Thiazide diuretics
Aquaporin				
Aquaporin-1	AQP1	Renal proximal tubule, thin descend- ing limb of the loop of Henle, erythrocyte	Colton blood group-null	None
Aquaporin-2	AQP2	Renal connecting tubule, collecting duct	Autosomal nephrogenic diabetes insipidus	None
Aquaporin-3	AQP3	Renal connecting tubule, collecting duct, erythrocyte	GIL blood group-null	None
Aquaporin-4	AQP4	Renal connecting tubule, collecting duct	None	None
Vasopressin-regulated urea channel	SLC14A2	Renal inner medullary collecting duct, thin descending limb of the loop of Henle	None	None
Epithelial sodium channel				
Beta subunit	SCNN1B	Renal connecting tubule, collecting duct	Type I pseudohypoaldoster- onism	Amiloride
Gamma subunit	SCNN1G	Renal connecting tubule, collecting duct	Type I pseudohypoaldoster- onism	Amiloride

<sup>\*</sup> Data are from the Online Mendelian Inheritance in Man database.



### POLYURIA AND POLYDIPSIA

Physiologic vs pathologic

Ambient temperature/humidity

Activity level

Dietary factors

Medications

## POLYURIA AND POLYDIPSIA

Polyuria vs Pollakiuria

Lower urinary tract disease

Diagnostic approach

UA's, urine culture and sensitivity

Imaging: radiographs, US, contrast studies

### POLYURIA AND POLYDIPSIA

Owner Assessment

Subjective

Water consumption at home

Hospitalization

Measurement of water consumption and urine output

## POLYURIA AND POLYDIPSIA

Normal Water Consumption

40 - 60 mls/kg day

Laboratory animals

**Abnormal Water Consumption** 

 $> 100 \, \text{mls/kg/day}$ 

## POLYURIA AND POLYDIPSIA

Diagnostic Approach

Documentation of pu/pd

Physical examination

Urinalysis

Sp gravity

Sediment and dip stick exam

Culture and sensitivity

CBC, serum chemistries

Renal Disease

Diabetes Mellitus

Liver Disease

Hyperthyroidism

Hyperadrenocorticism

Diabetes Insipidus

**CDI** 

NDI

Hypercalcemia

Hypoadrenocorticism

Pyometra

Hypokalemia

Polycythemia

Medications

Psychogenic

Renal Disease

Pyelonephritis >

CRF >

Fanconi's >

Post-obstructive >

diuresis

**Endotoxins** 

Loss of nephrons

Glycosuria

Osmotic diuresis

Diabetes Mellitus

Hyperglycemia
Glycosuria and/or ketonuria
Osmotic diuresis

Liver Disease

Medullary washout

Decreased urea production

Low BUN

Altered release of ADH

Altered GABA and dopaminergic tone

Increased secretion of cortisol

Hyperthyroidism

Increased GFR
Increased renal blood flow
Psychogenic

Hypercalcemia

Renal tubular mineralization

Alteration in renal blood flow

Renal artery vasoconstriction

Altered release of ADH

Tubular resistance to ADH

Hyperadrenocorticism

Altered release of ADH
Tubular resistance to ADH
Concurrent UTI's
Pyelonephritis

85 % of patients will be pu/pd

Hypoadrenocorticism

Mechanism unknown

Renal Na loss

Osmotic diuresis

20-25 % of patients will be pu/pd

Pyometra

Concurrent pyelonephritis

E. coli endotoxins

Tubular resistance to ADH

#### Hypokalemia

Tubular vacuolization

Tubular resistance to ADH

Usually in conjunction with other causes of pu/pd

Polycythemia (PCV > 65 %)

Altered CNS blood flow
Altered release of ADH
Altered renal blood flow
Tubular resistance to ADH

#### Medications

Steroids

Anticonvulsants

Diuretics


Salts

Na or K bromide

Central Diabetes Insipidus

Failure to manufacture, store or secrete ADH

Congenital Acquired



Nephrogenic Diabetes Insipidus

Congenital lack of tubular receptors for ADH

Extremely rare in veterinary medicine

### DIAGNOSTIC APPROACH

Completion of Initial Data Base

Normal physical examination

Normal laboratory work

Differential Diagnosis

Hyperadrenocorticism, diabetes insipidus, portosystemic shunt (young animals), psychogenic

Other differentials have been eliminated

No signs of azotemia/dehydration

Close owner monitoring

Gradual water restriction

ADH administration

Gradual water restriction at home for

2 - 3 days

Re-establishment of medullary gradient

Failure to perform gradual water restriction will result in poor response to ADH

**DDAVP** 

1-2 drops into the conjunctival sac once to twice a day

2 to 5 mcg SQ q12h-q24h

Oral 0.1 to 0.2 mg PO once to twice a day

Interpretation

Central Diabetes Insipidus

No response to water restriction

Marked increase in urine sp gravity

with DDAVP

Interpretation

Nephrogenic Diabetes Insipidus

No response to water restriction

No increase in urine sp gravity

with DDAVP

### TREATMENT OF CENTRAL DIABETES INSIPIDUS

Constant access to free water DDAVP

1-2 drops into the conjunctival sac once to twice a day

2 to 5 mcg SQ q12h–q24h

Oral 0.1 to 0.2 mg once to twice a day

Expense

### TREATMENT OF NEPHROGENIC DIABETES INSIPIDUS

Constant access to free water

Salt restriction

Thiazide diuretics

Hydrochlorthiazide 2 - 4 mg/kg BID

Loop diuretics such as furosemide will not be effective

### PROGNOSIS FOR CENTRAL DIABETES INSIPIDUS

Congenital form
Other pituitary abnormalities
TSH, ACTH, GH, FSH, LH

Adult-onset form

High incidence of pituitary/hypothalamic neoplasia

### PROGNOSIS FOR NEPHROGENIC DIABETES INSIPIDUS

Monitor renal function

May progress to chronic renal failure

Only mild to moderate reductions in pu/pd with medical management